Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1988004665 - NOUVEAU POLYPEPTIDE DERIVE DE LA TOXINE DE LA COQUELUCHE ET SES APPLICATIONS

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. A polypeptide of the formula

H-X1-Gln-Thr-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr- -Ser-Arg-Arg-Ser-Val-Ala-Ser-X2-Y

in which X 1 and X2 each represents an optional coupling- -facilitating amino acid residue, and Y represents
-OH or -NH2.
2. An artificial compound in free or carrier--associated form with the capability of binding to glyco-conjugates, c h a r a c t e r i s e d in that it is chosen from the group consisting of the polypeptide of the formula

H-X1-Gln-Thr-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr- -Ser-Arg-Arg-Ser-Val-Ala-Ser-X2-Y

in which X 1 and X2 each represents an optional coupling- -facilitating amino acid residue, and Y represents
-OH or -NH2; and functional analogues and functional derivatives thereof.
3. An artificial compound in free or carrier--associated form with the capability of binding to immunoglobulins, c h a r a c t e r i s e d in that it is chosen from- the group consisting of the peptide of the formula

H-X1-Gln-Thr-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr- -Ser-Arg-Arg-Ser-Val-Ala-Ser-X2-Y

in which X 1 and X2 each represents an optional coupling- -facilitating amino acid residue, and Y represents -OH or -NH2; and functional analogues and functional derivatives thereof.
4. An artificial pertussis toxin antigen,
c h a r a c t e r i s e d in that it mainly consists of at least one peptide sequence reacting with antibodies induced by the native pertussis toxin selected from the group consisting of

the polypeptide

H-X1-Gln-Thr-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr- -Ser-Arg-Arg-Ser-Val-Ala-Ser-X2-Y

in which X 1 and X2 each represents an optional coupling- -facilitating amino acid residue, and Y represents
-OH or -NH2;
and parts thereof.
5. A diagnostic immunoassay kit for the determination of antibodies induced by the native pertussis toxin in a sample of biological fluid, c h a r a c t e r i s e d in that it comprises as a diagnostic antigen at least one antigen selected from artificial antigens which mainly consist of at least one peptide sequence reacting with antibodies induced by the native pertussis toxin selected from the group consisting of

the polypeptide

H-X1-Gln-Thr-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr- -Ser-Arg-Arg-Ser-Val-Ala-Ser-X2-Y

in which X 1 and X2 each represents an optional coupling- -facilitating amino acid residue, and Y represents
-OH or -NH2;
and parts thereof.

6. A diagnostic immunoassay kit according to claim 5, c h a r a c t e r i s e d in that there is additionally included
a carrier to which said diagnostic antigen is
coupled,
a positive standard serum sample,
a negative standard serum sample, and
optionally buffer solution(s) and/or washing solution(s).
7. A diagnostic immunoassay kit according to claim 6, c h a r a c t e r i s e d in that there is additionally included agar or agarose gel, or radioactively labelled antigen, or an enzyme conjugate and optionally a substrate for the enzyme conjugate.
8. A vaccine composition c h a r a c t e r i s e d in that it comprises as an immunizing component, at least one antigen selected from artificial pertussis toxin antigens, which mainly consist of at least one peptide sequence reacting with antibodies induced by the native pertussis toxin selected from the group consisting of
the polypeptide

H-X1-Gln-Thr-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr- -Ser-Arg-Arg-Ser-Val-Ala-Ser-X2-Y

in which X 1 and X2 each represents an optional coupling- -facilitating amino acid residue, and Y represents
-OH or -NH2;
and parts thereof,
together with a nontoxic pharmaceutically acceptable carrier and/or diluent.
9. A vaccine composition according to claim 8, c h a r a c t e r i s e d in that it comprises said pertussis toxin antigen(s) in an amount effective to protect a subject from the disease whooping cough.
10. A vaccine composition according to claim
8, c h a r a c t e r i s e d in that it further comprises an antigen adjuvant in an amount which together with an amount of said pertussis toxin antigen (s) is effective to protect a subject from the disease whooping cough.
11. A vaccine composition according to claim 8,

9 or 10, c h a r a c t e r i s e d in that it additionally comprises buffer (s) and/or preservative (s).
12. An intradermal skin test composition c h a r a c t e r i s e d in that it comprises at least one antigen in an amount effective to produce an immunological skin reaction at a specific antibody titre in a subject, said antigen being selected from artificial pertussis toxin antigens, which mainly consist of at least one peptide sequence reacting with antibodies induced by the native pertussis selected from the group consisting of

the polypeptide

H-X1-Gln-Thr-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr- -Ser-Arg-Arg-Ser-Val-Ala-Ser-X2-Y

in which X 1 and X2 each represents an optional couplmg- -facilitating amino acid residue, and Y represents
-OH or -NH2;
and parts thereof,
together with a nontoxic pharmaceutically acceptable carrier and/or diluent.
13. An intradermal skin test composition according to claim 12, c h a r a c t e r i s e d in that it further comprises buffer(s) and/or preservative (s).